Blackstone Life Sciences

Blackstone Life Sciences, established in 2005, is a private equity firm specializing in the life sciences sector. Based in Cambridge, Massachusetts, with an additional office in South San Francisco, California, the firm invests in both early and late-stage biotechnology and healthcare companies. Blackstone Life Sciences focuses on biopharmaceuticals, specialty pharma, medical devices, and diagnostic spaces, with a particular interest in cancer drugs and treatments for inflammatory and urological disorders. The firm prefers risk-shared, co-development opportunities and structured financing deals, such as funding late-stage trials or buying royalties on drugs before approval. Blackstone Life Sciences targets investments in companies based in the United States and Europe, with a typical investment size ranging from $15 million to $100 million per company.

Emmett Cunningham

Senior Managing Director

Kurt Wheeler

Senior Managing Director

15 past transactions

AvenCell

Series B in 2024
Based on our deep science and focused on patients in need.

Uniquity Bio

Series A in 2024
Uniquity Bio is a clinical-stage drug development company dedicated to advancing innovative medicines, specifically in the fields of immunology and inflammation. The company aims to identify and develop therapeutic programs that offer transformative benefits to patients with limited or no treatment options. With leadership from experienced pharmaceutical executives, Uniquity Bio effectively drives its research and development efforts. The company has attracted notable investments, which support its mission to pursue groundbreaking drug development initiatives.

Moderna

Post in 2024
Moderna, Inc. is a biotechnology company established in 2010 and headquartered in Cambridge, Massachusetts. The company specializes in developing therapeutics and vaccines using messenger RNA (mRNA) technology, which provides instructions for cells to produce proteins essential for various biological functions. Moderna has a diverse pipeline, with numerous programs targeting infectious diseases, immuno-oncology, rare diseases, and cardiovascular conditions. As of September 2024, it has 40 mRNA development candidates in clinical trials across multiple therapeutic areas. The company's mRNA technology gained significant recognition with the authorization of its COVID-19 vaccine in December 2020. Moderna maintains strategic alliances with various organizations, including major pharmaceutical companies and research institutions, to enhance its research and development efforts.

Amicus Therapeutics

Post in 2023
Amicus Therapeutics, Inc. is a biotechnology company dedicated to the discovery, development, and commercialization of therapies for rare and orphan diseases. Founded in 2002 and headquartered in Cranbury, New Jersey, the company focuses on developing innovative treatments, including Galafold, an orally administered pharmacological chaperone for Fabry disease. Amicus is also advancing its pipeline with a Phase 3 clinical study of AT-GAA for Pompe disease. The company's research includes a range of first-in-class small molecules designed to treat lysosomal storage diseases by stabilizing misfolded enzymes in patients. This therapeutic approach potentially enhances the effectiveness of enzyme replacement therapies. Amicus Therapeutics has established collaborations with institutions such as Nationwide Children's Hospital and the University of Pennsylvania to further its research and development efforts.

Sutro Biopharma

Post in 2023
Sutro Biopharma is a clinical-stage drug discovery, development, and manufacturing company based in South San Francisco, California. The company specializes in creating next-generation protein therapeutics aimed at treating cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Among its product candidates are STRO-001, an antibody-drug conjugate targeting CD74 for patients with multiple myeloma and non-Hodgkin lymphoma, and STRO-002, which is directed against folate receptor-alpha for individuals with ovarian and endometrial cancers. Sutro Biopharma also has a collaboration and licensing agreement with Celgene Corporation to develop bispecific antibodies and antibody-drug conjugates primarily in the field of immuno-oncology. Founded in 2003, the company continues to advance its innovative therapeutic candidates through rigorous clinical development.

PTC Therapeutics

Post in 2022
PTC Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of orally administered small-molecule therapeutics for the treatment of rare disorders and cancer. The company offers Translarna, used for nonsense mutation Duchenne muscular dystrophy in ambulatory patients, and Emflaza, a corticosteroid for the same condition. PTC Therapeutics is advancing several candidates in clinical development, including Translarna for other rare genetic conditions, RG7916 and RO7034067 for spinal muscular atrophy, and PTC596 and PTC299, which target cancer through dihydrooratate dehydrogenase inhibition. Additionally, the company is developing a gene therapy candidate, PTC-AADC, for Aromatic L-amino acid decarboxylase deficiency. PTC Therapeutics collaborates with various organizations, including F. Hoffman-La Roche Ltd and Massachusetts General Hospital, to further its research and commercialization efforts. Founded in 1998, the company is headquartered in South Plainfield, New Jersey.

Sanofi Oncology

Post in 2022
Sanofi Oncology, a division of global healthcare company Sanofi, focuses on developing and delivering innovative treatments for various types of cancer. With a rich heritage in oncology, Sanofi Oncology leverages its extensive knowledge base to research and treat cancer from multiple angles, addressing diverse patient needs and disease stages. The company's portfolio includes therapies for rare diseases, immunology, and cardiovascular conditions, among others. Sanofi's commitment to patients drives its strategy to create long-term value through innovative treatments, from research and development to manufacturing and marketing.

Harmony Biosciences

Post in 2021
Harmony Biosciences, established in 2017 and based in Plymouth Meeting, Pennsylvania, is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare neurological disorders. Its primary product, WAKIX (pitolisant), is a first-in-class medication designed to increase histamine signaling in the brain, approved for treating cataplexy in adult narcolepsy patients. Harmony Biosciences operates as a subsidiary of Harmony Biosciences Holdings, Inc., which is dedicated to addressing unmet medical needs in this therapeutic area.

Talaris Therapeutics

Series B in 2020
Talaris Therapeutics, Inc. is a biotechnology company focused on developing innovative cell therapies aimed at eliminating chronic immunosuppression in organ transplant recipients. Its lead product, FCR001, is designed to enable living donor kidney transplant recipients to discontinue all long-term immunosuppression therapy within twelve months of their transplant. Additionally, the company's technology facilitates the safe administration of hematopoietic stem cells from unmatched and unrelated donors for bone marrow transplants, minimizing the risks associated with traditional methods. Founded in 1988 and based in Louisville, Kentucky, with an office in Wellesley, Massachusetts, Talaris Therapeutics has transitioned from its former name, Regenerex, Inc., in March 2019. The company is currently in the late stages of clinical development, also exploring applications for patients with severe autoimmune and immune-mediated disorders.

Annexon Biosciences

Series D in 2020
Annexon Biosciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients suffering from classical complement-mediated disorders affecting the body, brain, and eye. The company's research is centered around its platform technology that targets classical complement-mediated autoimmune and neurodegenerative diseases associated with the abnormal activation of C1q, a key molecule in the classical complement pathway. Annexon's lead product candidate, ANX005, is a full-length monoclonal antibody intended for intravenous use in treating autoimmune and neurodegenerative disorders. Another candidate, ANX007, is a monoclonal antibody Fab formulated for intravitreal administration aimed at neurodegenerative ophthalmic conditions. The company employs a disciplined, biomarker-driven development strategy to ensure its therapies effectively engage the target at tolerable doses within the intended patient tissues, while also exploring additional indications within both orphan and larger market segments.

Medtronic

Post in 2020
Medtronic is a global leader in healthcare technology, specializing in innovative solutions for complex medical conditions. The company offers a wide range of treatments and therapies, including patient monitoring systems, robotic surgery, insulin pumps, and cardiac devices, catering to various health areas such as lungs, brain, diabetes, heart, and orthopedics. Medtronic's extensive portfolio addresses 70 different medical conditions, aiming to improve and extend the lives of patients worldwide.

Reata Pharmaceuticals

Post in 2020
Reata Pharmaceuticals is a clinical-stage biopharmaceutical company that develops innovative therapeutics aimed at treating serious and life-threatening diseases by targeting molecular pathways involved in cellular metabolism and inflammation. The company is advancing several clinical trial programs, including bardoxolone methyl for chronic kidney disease related to Alport syndrome and pulmonary arterial hypertension, as well as omaveloxolone for Friedreich’s ataxia. Additionally, Reata is conducting studies for various forms of chronic kidney disease, including IgA nephropathy and diabetic kidney disease. The company is also developing RTA 901 for neurological conditions such as diabetic neuropathy and exploring RORgT inhibitors in preclinical stages for autoimmune and fibrotic diseases. Reata has strategic collaborations with Kyowa Kirin to develop bardoxolone in several Asian markets and with AbbVie to research second-generation Nrf2 activators for various indications. Founded in 2002 and headquartered in Plano, Texas, Reata Pharmaceuticals was previously known as Reata Discovery, Inc. until its name change in 2005.

Alnylam Pharmaceuticals

Post in 2020
Alnylam Pharmaceuticals is a biopharmaceutical company specializing in the discovery, development, and commercialization of RNA interference (RNAi) therapeutics. The company focuses on addressing rare genetic diseases, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system/ocular disorders. Its marketed products include ONPATTRO, a treatment for hereditary transthyretin-mediated amyloidosis, and GIVLAARI, which targets acute hepatic porphyria. Alnylam’s pipeline includes investigational therapies such as givosiran for acute hepatic porphyria, lumasiran for primary hyperoxaluria type 1, and vutrisiran for transthyretin amyloidosis. The company has established strategic alliances with notable partners like Sanofi Genzyme and Regeneron Pharmaceuticals, and it collaborates with Vir Biotechnology on RNAi therapeutics for coronavirus infections. Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam Pharmaceuticals is at the forefront of transforming RNAi science into innovative medicines to improve patient outcomes.

Anthos Therapeutics

Series A in 2019
Anthos Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative therapies for cardiovascular and metabolic diseases. Founded in 2018, the company specializes in treatments targeting Factor XI and XIa, essential components of the intrinsic coagulation pathway. Its lead product, MAA868, is an antibody designed to provide an anti-thrombotic effect, allowing healthcare professionals to prevent various thrombotic diseases while minimizing the risk of bleeding. By advancing long-acting treatment options, Anthos Therapeutics aims to improve care for patients suffering from cardiovascular conditions, representing a significant advancement over conventional therapies.

GRIN Therapeutics

GRIN Therapeutics is a clinical-stage biotechnology company dedicated to developing precision therapeutics for serious pediatric neurodevelopmental disorders.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.